PMID- 38260125
OWN - NLM
STAT- MEDLINE
DCOM- 20240124
LR  - 20240305
IS  - 1664-2392 (Print)
IS  - 1664-2392 (Electronic)
IS  - 1664-2392 (Linking)
VI  - 14
DP  - 2023
TI  - A study of the relationship between cytokine levels and the response to anti-VEGF 
      therapy in polypoid choroidal vasculopathy with different choroidal thicknesses.
PG  - 1307337
LID - 10.3389/fendo.2023.1307337 [doi]
LID - 1307337
AB  - PURPOSE: Polypoidal choroidal vasculopathy (PCV) is an irreversible retinal 
      choroidal disease. Individuals with PCV exhibit diverse baseline characteristics, 
      including systemic characteristics, ocular traits, metabolic factor levels, and 
      different responses to intravitreal anti-VEGF therapy. This study aims to 
      investigate the pathogenesis of PCV by analyzing the systemic characteristics, 
      ocular traits, and cytokine levels at baseline within a cohort of patients who 
      exhibit different responses to anti-VEGF treatment. METHODS: We conducted a 
      retrospective analysis involving 80 eyes diagnosed with PCV. Patients were 
      categorized into two groups based on responses to suboptimal intravitreal 
      ranibizumab injection therapy: those with suboptimal responses and optimal 
      responses. Aqueous humor samples were collected from the experimental eyes, and 
      cytokine expression levels were assessed using cytometric bead array analysis. 
      All subjects were further stratified into two groups according to the median 
      choroidal thickness. Subsequently, logistic regression analysis and the ROC curve 
      were employed to examine the relationship between cytokine expression levels, 
      choroidal thickness, and anti-VEGF response. RESULTS: The results revealed that 
      compared to the group of optimal anti-VEGF response, the choroid in the 
      suboptimal response group exhibited a significantly greater thickness. 
      Additionally, compared to the suboptimal anti-VEGF response group, the expression 
      levels of VEGF and VCAM-1 were markedly lower observed in the optimal anti-VEGF 
      response group, while TNF-alpha showed the opposite trend. Logistic regression 
      analysis indicated that VEGF, VCAM-1, and TNF-alpha in the aqueous humor were 
      independent risk factors for a suboptimal anti-VEGF response. After adjusting 
      other risk factors, the risk of suboptimal anti-VEGF response decreased to 
      0.998-fold, 0.997-fold, and 1.294-fold. The AUC values for VEGF, VCAM-1, and 
      TNF-alpha were determined to be 0.805, 0.846, and 0.897, respectively. Furthermore, 
      the risk of VEGF, VCAM-1, and TNF-alpha were significantly associated with an 
      increased risk of suboptimal anti-VEGF response after correction for risk factors 
      in the thick choroid group. CONCLUSIONS: Our study demonstrated that PCV exhibits 
      systemic and ocular characteristics variations based on different anti-VEGF 
      responses. The levels of cytokines in aqueous humor were found to have a 
      significant correlation with the anti-VEGF response in PCV. VEGF, VCAM-1, and 
      TNF-alpha are potential targets for assessing treatment response in thick choroidal 
      PCV.
CI  - Copyright (c) 2024 Dong, Fan, Yu, Jiang and Sun.
FAU - Dong, Su
AU  - Dong S
AD  - Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Fan, Pan
AU  - Fan P
AD  - Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Yu, Haotian
AU  - Yu H
AD  - Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Jiang, Bo
AU  - Jiang B
AD  - Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
FAU - Sun, Dawei
AU  - Sun D
AD  - Department of Ophthalmology, The Second Affiliated Hospital of Harbin Medical 
      University, Harbin, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20240103
PL  - Switzerland
TA  - Front Endocrinol (Lausanne)
JT  - Frontiers in endocrinology
JID - 101555782
RN  - 0 (Cytokines)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Vascular Cell Adhesion Molecule-1)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
MH  - Humans
MH  - *Cytokines
MH  - *Tumor Necrosis Factor-alpha
MH  - Retrospective Studies
MH  - Vascular Cell Adhesion Molecule-1
MH  - Vascular Endothelial Growth Factor A
MH  - Choroid
PMC - PMC10802117
OTO - NOTNLM
OT  - anti-vascular endothelial growth factor
OT  - biomarker
OT  - choroidal thicknesses
OT  - cytokine
OT  - pachychoroid
OT  - polypoidal choroidal vasculopathy
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2024/01/23 12:44
MHDA- 2024/01/24 06:44
PMCR- 2023/01/01
CRDT- 2024/01/23 10:34
PHST- 2023/10/04 00:00 [received]
PHST- 2023/12/07 00:00 [accepted]
PHST- 2024/01/24 06:44 [medline]
PHST- 2024/01/23 12:44 [pubmed]
PHST- 2024/01/23 10:34 [entrez]
PHST- 2023/01/01 00:00 [pmc-release]
AID - 10.3389/fendo.2023.1307337 [doi]
PST - epublish
SO  - Front Endocrinol (Lausanne). 2024 Jan 3;14:1307337. doi: 
      10.3389/fendo.2023.1307337. eCollection 2023.